Lantus Injection 100 Iu/ml 3 ml Cartridge

Lantus Injection 100 Iu/ml 3 ml Cartridge is a prescription based long-acting type of insulin with active ingredient Insulin Glargine (100IU/ml). It is used in the treatment of type 1 and 2 diabetes mellitus in both adults & children.

Glaritus give a stable level of insulin in the body for an entire day and helps to control blood sugar levels. This medicine also helps to prevent complications associated with diabetes.

Healthcare provider will teach the proper way of injecting it under the skin correctly. It can be prescribed alone or in combination with fast-acting insulin or other diabetes medicines.​

• Type 1 and 2 diabetes mellitus

Side effects are undesirable symptoms that can result from any medical treatment. Like any other medicine, Lantus Injection 100 Iu/ml 3 ml   also causes some adverse impact on the body, most of which resolve without any medical attention.

Some common side effects include:

• Edema (swelling)
• Allergic reaction
• Injection site reactions (pain, swelling, redness)
• Rash
• Lipodystrophy (skin thickening or pits at the injection site)
• Itching
• Weight gain
• Hypoglycemia (low blood glucose level)

Seek medical attention in case of any unusual or severe side effects immediately.

• Dosage of the Lantus Injection 100 Iu/ml 3 ml decide according to the type of diabetes and overall health condition of the patient. This injection can be administered by a doctor or nurse or your care giver may be taught on how to use this medicine at home.
• In case of an overdose, the doctor will provide emergency medical treatment. Do not stop or change the dose without informing your doctor.

• Lantus Injection 100 Iu/ml 3 ml is a prescription based long-acting type of insulin. it helps to treat type 1 & type 2 diabetes by providing consistent and all-day sugar control. It works like the body's natural insulin.
• Insulin facilitates the reuptake of sugar in muscle and fat cells as well as suppresses sugar production in the liver.​
  

• Haque, M., Islam, S., Abubakar, A. R., Sani, I. H., Opanga, S., Kamal, Z. M., ... & Godman, B. (2021). Utilisation and expenditure on long-acting insulin analogues among selected middle-income countries with high patient co-payment levels: findings and implications for the future. Journal of Applied Pharmaceutical Science.
• Song, D., & Davidson, J. (2007). Cross-reactivity of Actrapid and three insulin analogues in the Abbott IMx insulin immunoassay. Annals of clinical biochemistry, 44(2), 197-198.
• Danne, T., Bangstad, H. J., Deeb, L., Jarosz‐Chobot, P., Mungaie, L., Saboo, B., ... & Hanas, R. (2014). Insulin treatment in children and adolescents with diabetes. Pediatric diabetes, 15.
• DeSouza, C., Cariou, B., Garg, S., Lausvig, N., Navarria, A., & Fonseca, V. (2020). Efficacy and safety of semaglutide for type 2 diabetes by race and ethnicity: a post hoc analysis of the SUSTAIN trials. The Journal of Clinical Endocrinology & Metabolism, 105(2), 543-556.
• Haque, M., Islam, S., Kamal, Z. M., Akter, F., Jahan, I., Rahim, M. S. A., ... & Godman, B. (2021). Ongoing efforts to improve the management of patients with diabetes in Bangladesh and the implications. Hospital practice, 49(4), 266-272.
• Nosrati, M., Ahmadi Fariman, S., Saiyarsarai, P., & Nikfar, S. (2023). Pharmacoeconomic evaluation of insulin aspart and glargine in type 1 and 2 diabetes mellitus in Iran. Journal of Diabetes & Metabolic Disorders, 22(1), 817-825.
• Bhandarkar, A., Kumar, B. K., Praveen, V. P., & Chandramathi, J. (2025). Effective use of saline-diluted subcutaneous glargine in very low birth weight babies with neonatal hyperglycemia. Journal of Family Medicine and Primary Care, 14(8), 3542-3545.